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Abstract 
To determine, in non-diabetic women, the relationship of abnormal glucose screening test, with the
incidence of pre-eclampsia, macrosomia and caesarian delivery, from 1988-92, 5646 consecutive
women attending antenatal clinic were screened with a glucose challenge test (GCT) on their first visit
(usually at 16-20 weeks); those with risk factors i.e., history of unexplained perinatal loss, macrosomia
or family member with diabetes and an initial abnormal screening test were rescreened at 28-32 weeks,
In 482 cases the GCT was abnormal (plasma glucose value was >140 mg% 2 hours after 75g glucose
challenge). Of these, 292 had one or more abnormal critical values at a 75g -3 hour oral glucose
tolerance test (GTT) and they were treated to maintain euglycaemia. The rest (n=190) had no evidence
of glucose intolerance with no abnormal values at the GTT. The subjects were divided into 3 groups
based on GCT values; A, randomly selected subjects with a normal GCT (n=1000); B, those with
abnormal GCT but normal GTT (n=190); and C, those with abnormal GTT (n=292). The variables
studied were age, gravidity, parity, gestational age at delivery, pre-eclampsia, birth-weight and mode of
delivery. The incidence of pre-eclampsia and caesarian birth varied, being the lowest in Group A (3.9%
and 11.9% respectively) and then rising through group B (6.3% and 16.3% respectively) to the highest
in Group C (12.6% and 26.0% respectively; test of linear trend, p<0.05). For macrosomia, the
incidence increased from Group A to B but there was a drop in Group C. The incidence of macrosomia
was significantly higher for Group B as compared to A or C (9.5% and 3.3%, p 
Introduction 
Pre-eclampsia, fetal macrosornia and high caesarian rates are well known to be associated with
carbohydrate intolerance in pregnancy. These and other complications lead to a high morbidity and
mortality in diabetes mellitus during pregnancy1. The present criteria requiring two abnormal glucose
tolerance test (GTT) values for diagnosis of gestational diabetes mellitus (GDM), are not strict enough
to screen for these complication2-4. In addition, there are several different GUs and those with high
thresholds do not identify a high numberof gestational diabetics5, leaving these pregnancies at risk. The
relation of pregnancy complications to sub-diabetic elevations of maternal plasma glucose levels has
been demonstrated using one abnonnal GTT value as a risk indicator3,4. The association of known
complications of gestational diabetes with minor degrees of hyperglycemia, which may not be
detectable by a Gil’. needs further evaluation. At the Aga Khan University Medical Centre, Karachi,
screening with a 75g -2 hour glucose challenge test (GCT) is performed routinely for all women
attending antenatal clinics6. We thus had the opportunity to examine the relationship of plasma glucose
value in the GCT, in women with no evidence of glucose intolerance, with incidence of some known
complications of diabetes mellitus in pregnancy.
Subjects and Methods 
This study was carried out at the Aga Khan University Hospital, Karachi, where general and tertiary
health care facilities are provided to a sell-referred population. In the obstetrics division, since January,
1988, all pregnant women not known to be diabetic were screened for gestational diabetes as described
in detail elsewhere6. The screening test consisted of a 75 g OCT in which a single venous blood
sample, obtained 2 hours after oral glucose administration, was used for plasma glucose estimation
(hexokinase method with an autoanalyser).The glucose load was administered in 300 mls of fluid given
orally over a 5 minute period. Fasting was not required. This test was administered first at the initial
booking visit (usually at 16-20 weeks gestation). If the plasma glucose value was 140 mg% or above,
the test was considered abnonnal and a formal 75g -3 hour oral Gil’ was carried out. The GCT was
repeated at 28-32 weeks on selected women. The criteria for repetition included an initial abnormal
GCT followed by normal GTT and presence of features of potential diabetes i.e., close family history
of diabetes, previous macrosomic baby and history of unexplained stillbirth/neonatal death. A repeat
GTF was performed if the plasma glucose value at the repeat OCT was 140 mg% or more. For
administration of the Gil’, all subjects consumed an unrestricted caibohydrate dietforatleast 3 days
priorto the test and came fasting for 10-12 hours on the morning of the GTT. The criteria used for
diaqnosing glucose intolerance were modified from O’Sullivan and reported in a recent literature
review5. They were the same as those used in our previous report6. Fasting, 1 hour, 2 hour and 3 hour
values of plasma glucose were used where values of >105 mg%, >186 mg%,>140mg% and >122 mg%
respectively are considered abnormal. Two or more abnormal values were taken as evidence of 0DM
anda single abnormal value was considered impaired glucose tolerance test (JOT). All patients with
0DM and lOT were managed according to the same protocol. Plasma glucose series, with fasting, pre-
lunch and post-dinner values, were performed after initiation of dietary restriction to a high protein
2000 k cal diet. The plasma glucose series was repeated every 2-4 weeks depending on the plasma
glucose values, lithe fasting value was >110 mg% or if the pre-lunch or post-dinner value was >140 mg
%, insulin was added to dietary restriction and plasma glucose series was monitored every 2 weeks.
The time and mode of delivery was decided according to glycemic control and presence of
complications by the consultant obstetrician. Over a four years period between June, 1988 and June,
1992 a total of 5646 women were screened and managed according to this protocol. The prevalence of
abnonnal OCT in this group was 8.6% (n=482; 278 had an abnormal GCT at initial screen and 204
atrescreen). The data fora control group in this study were obtained from a database of 1000 cases
chosen by simple random selection out of 5 164women with a normal OCT (group A). The 482 women
with an abnormal OCT underwent a GTT. The group studied consisted of 190 women with an abnormal
OCT but a normal GTT (group B). Anabnormal OTTwasfound in 292 womcn(eitherODM: 177 cases
orIGTT: 115 cases) including 55 with an abnormal Oil’ after rescreening at 28 weeks. These 292
women were managed by dietary restriction or diet/insulin therapy (group C). Thus in the three groups
A-C, group A represented those with normal glucose tolerance; group B those with minor glucose
intolerance as evident by abnormal GCT but required no therapy as OTT was normal and group C,
those with 0DM/JOT and receiving therapy for it. The variables studied were age, gravidity, panty,
gestational age at delivery, birth-weight, pre-eclampsia and caesarianbirth. Gestational age was
determinedby the date of the last menstrual period if the preceding cycles were regular without use of
oral contraceptives and corresponded to physical examination and ultrasonography at <20 weeks’-
gestation. In case of uncertain dates gestational age was determined by ultrasonography on two
occasions that resulted in consistent estimates at <26 weeks’ gestation. Pre-eclampsia was defined as
combination of hypertension (B.P.> 140/90 mmHg) and proteinuria (>300 mg%) developing after 20
weeks’ gestation. Macrosomia was defined as a birth-weight of 4 kg or more. The data were analyzed
with the Statistical Package for Social Science (SPSS/PC+). Analysis of variance (ANOVA) was used
for normally distributed variables and Kruskal-Wallis test was used for those not normally distributed
(gravidity and panty). The test of linear trend in proportions was used to determine trends. Chi-square
test and Student’s ‘t’ test were used to assess difference between proportions and means respectively. A
‘p’ value of <0.05 was taken as significant.
Results 
Table I shows the mean values of age, gravidity, parity, gestational age at delivery and birth-weight in
the different groups of OCT results. The prevalence of risk factors is also shown. Subjects with higher
OCT values were older (ANOVA); p0.05), although gravidity was higher in subjects with higher degree
of glucose intolerance (ANOVA; p<0.05). The gestational age at delivery did not show any variance in
different groups (ANOVA; p>O.O5), although that for group C was lowerthan A orB. The meanbirth-
weight was lower in groups A and C (p<0.O5). The rate of family history of diabetes and that of histoiy
of unexplained perinatal loss showed a higher trend in groups B and C (Test of linear trend: p
Table II shows the frequency/incidence of pre-eclampsia, macrosomia and caesarian birth in the
different groups of GCT values. As the glucose tolerance became worse, the incidence of pre-eclampsia
and caesarian birth varied, being lowest in group A and highest in group C (Test of linear trend:p).
However, for macrosomia, the incidence increased as the GCT value increased from Group A to B but
there was a drop in Group C. The incidence of macrosomia was higher for group B as compared to A or
C (p<0.05).
Discussion 
The aim of screening is to use a simple and affordable test with acceptable sensitivity and specificity to
identify risk population early enough to perform diagnostic test and institute therapy in order to
improve outcome. Numerous publications on screening strategies for GDM have been critically
reviewed8,9 and the estimation of blood glucose hour after 50 g oral glucose load was found to be the
most commonly used test for screening8. There was lack of consensus on the screening threshold of the
blood glucose value and the worth of such screening has been openly questioned9. In these reviews the
use ofa75 g glucose load for glucose screening test has notbeenevaluated. The 75g glucose load for
screening was recommended by the WHO10. There is sufficient evidence that a 2 hour time interval
improves specificity of the GCT11. Increasing the load of glucose from 50g to 75g is also known to
improve the efficiency of the GCT12. Successful experience with such screening has been documented
invarious reports6,13. The sensitivity of this testis 83% and specificity 90.7%13 which is similar, if not
superior, to the 79% sensitivity and 87% specificity of the 50 g glucose screening test8. The question of
timing of the GCT has been’ asked in several reports and more recent literature is in support of earlier
screening14. We initially screened at 16-20 weeks gestation and then rescreened at 28 weeks which has
been (in~u shown to. be the optimum time for detecting gestational diabetes. Pre-eclampsia, a disorder
of unknown etiology, is associated with high rate of mothidity and mortality. This disorder is known to
occur more frequently in 0DM as well as in IGT1,3. This study shows that the incidence of pre-eclamp-
sia increases dramatically with worsening degree of glucose intolerance (Table II) Similartrend was
seenby Tallarigoctal using 2 hour plasma glucose value in a 100g GTT2. Early pregnancy proteinuria is
reported to be associated with pre-eclampsia in GDM15. It has been speculated that poor glycemic
control in the second trimester might interfere with the second wave of trophoblastic invasion16 or
some direct effect ofglucose on the vascular epithelium could predispose to hypertensive disorder in
diabetic women15. Frequent use of elective delivery and other complications like macmsomia lead to
high caesarian rates in women with diabetes1,17. Our data (Table II) suggests that for caesanan deliveiy
a linear trend exists with worsening caibohydrate intolerance similar to that shown by Tallarigo et al2.
Hence, non-diabetic women with abnormal glucose screening test (group B) are at higher risk than
those with nonnal screening (group A). This may have been so because one is more easily inclined to
intervene with a caesarian in women withprevious perinatal loss and such histoiy was more frequent in
group B than A (Table I). In addition, pre-eclampsiaand macrosomia were also more frequent in group
B (Table II) which might have resulted ma high caesarian rate. Foetal macrosomia is associated with
increased risks of maternal and neonatal morbidity. In this study macmsomia was more frequent in
group B as compared to A or C (p<0.01). Gestational age at deliveiy is a major determinant of birth-
weight4,17. Mean gestational age at delivery were similar in groups A and B, but lower in group C
(Table I). Early elective delivery may have been responsible for restriction of foetal size in group C. In
addition, the incidence of pre-eclampsia was highest in this group and hypertension has been shown to
have a negative effect on birth-weight in treated diabetic pregnant women18. In non-diabetic women
like those in groups A and B, the studies on the association between macrosomia and minor degrees of
glucose intolerance, using a 50 gglucose screening test have been inconclusive19. With a 75 g glucose
load, we found that an increasing plasma glucose value at OCT from <65 mg% to >140 mgk% was
associated with an increasing incidence of macrosomia from 1.2% to 9.5% (Test of linear trend:
p’<0.01). This trend was reproducible after controlling for panty and gdstational age. As proposed
hypotheses have related foetal growth to foetal insulin21 and maternal glucose levels22, we hypothesize
that women with minor degrees of glucose intolerance had macrosomic babies due to mild maternal
hyperglycemia significant enough to cause foetal hypennsulinemia. The high incidence of poor
pregnancy outcome in women with abnormal glucose screening but normal GTT (Table II) could be
explained by the lack of reproducibility in the GTT5. This may have led a number of women in this
study to have one or two abnormal values if the test was repeated subsequently. It is more likely, we
believe, that in the present series, womenwithminordegrees of carbohydrate intolerance (group B) had
complications due to mild though significant hyperglycemia. The association of high rates of pre-
eclampsia, macrosomia andcaesananbirth with sucha limited degree of glucose intolerance warrants
that anticipatory counseling regarding these risks be offered to women with abnormal glucose
screening tests.
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